Humate-P: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
*[[Hemophilia]] A (can also use factor VIII, [[FFP]] does not work well) | *[[Hemophilia]] A (can also use factor VIII, [[FFP]] does not work well) | ||
*Von Willebrand disease that is unresponsive to DDAVP (can also use [[cryoprecipitate]], [[FFP]] does not work well) | *Von Willebrand disease that is unresponsive to DDAVP (can also use [[cryoprecipitate]], [[FFP]] does not work well) | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[blood products]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: | ||
| Line 17: | Line 14: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Von Willebrand disease]] | |||
**Major hemorrhage: loading dose 40-80 IU/kg IV | |||
**Minor hemorrhage: loading dose 40-50 IU/kg IV | |||
*[[Hemophilia]] A | |||
**Minor hemorrhage: Loading dose 15 IU/kg IV should achieve FVIII:C plasma level ~30% of normal | |||
**Moderate hemorrhage: Loading dose 25 IU/kg IV should achieve FVIII:C plasma level ~50% of normal | |||
**Life-threatening hemorrhage: 40-50 IU/kg IV initially, followed by 2-25 IU q8-12hr to maintain FVIII:C level at 80-100% of normal | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*[[Von Willebrand disease]] | |||
**Major hemorrhage: loading dose 40-80 IU/kg IV | |||
**Minor hemorrhage: loading dose 40-50 IU/kg IV | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Data limited | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *Not delineated | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
* | *Not established | ||
* | |||
==Contraindications== | |||
*Allergy to class/drug | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Respiratory distress | |||
*Anaphylaxis | |||
*Thromboembolic events | |||
*Hemolytic anemia (in massive doses) | |||
===Common=== | ===Common=== | ||
*Pain | |||
*Pruritus | |||
*Rash, urticaria, edema | |||
*Fever/chills, flu-like illness, cough, pharyngitis, rhinitis | |||
*Paresthesia | |||
*Fatigue | |||
*Headache | |||
*Asthenia | |||
*Cellulitis | |||
*Chest pain | |||
*Dyspepsia, nausea/vomiting | |||
*Hepatitis | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 10-11h | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Human derived vWF | |||
==Comments== | ==Comments== | ||
| Line 49: | Line 71: | ||
==See Also== | ==See Also== | ||
*[[Hemophilia]] | |||
*[[VWD]] | |||
==References== | ==References== | ||
Revision as of 19:28, 1 October 2019
Background
- Human Plasma-derived von Willebrand Factor
- Contains both vWF and factor VIII
Indications
- Hemophilia A (can also use factor VIII, FFP does not work well)
- Von Willebrand disease that is unresponsive to DDAVP (can also use cryoprecipitate, FFP does not work well)
Administration
- Type: blood products
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
- Von Willebrand disease
- Major hemorrhage: loading dose 40-80 IU/kg IV
- Minor hemorrhage: loading dose 40-50 IU/kg IV
- Hemophilia A
- Minor hemorrhage: Loading dose 15 IU/kg IV should achieve FVIII:C plasma level ~30% of normal
- Moderate hemorrhage: Loading dose 25 IU/kg IV should achieve FVIII:C plasma level ~50% of normal
- Life-threatening hemorrhage: 40-50 IU/kg IV initially, followed by 2-25 IU q8-12hr to maintain FVIII:C level at 80-100% of normal
Pediatric Dosing
- Von Willebrand disease
- Major hemorrhage: loading dose 40-80 IU/kg IV
- Minor hemorrhage: loading dose 40-50 IU/kg IV
Special Populations
- Pregnancy Rating: C
- Lactation risk: Data limited
Renal Dosing
- Not delineated
Hepatic Dosing
- Not established
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Respiratory distress
- Anaphylaxis
- Thromboembolic events
- Hemolytic anemia (in massive doses)
Common
- Pain
- Pruritus
- Rash, urticaria, edema
- Fever/chills, flu-like illness, cough, pharyngitis, rhinitis
- Paresthesia
- Fatigue
- Headache
- Asthenia
- Cellulitis
- Chest pain
- Dyspepsia, nausea/vomiting
- Hepatitis
Pharmacology
- Half-life: 10-11h
- Metabolism:
- Excretion:
Mechanism of Action
- Human derived vWF